After-exercise heart rate variability is attenuated in postmenopausal women and unaffected by estrogen therapy

This item was submitted to Loughborough University's Institutional Repository by the/an author.

Citation: HARVEY, P.J. ... et al., 2016. After-exercise heart rate variability is attenuated in postmenopausal women and unaffected by estrogen therapy. Menopause, 23 (4), pp. 390-395.

Additional Information:

• This article was accepted for publication in the journal, Menopause [Lippincott, Williams & Wilkins © The North American Menopause Society].

Metadata Record: https://dspace.lboro.ac.uk/2134/20601

Version: Accepted for publication

Publisher: Lippincott, Williams & Wilkins © The North American Menopause Society

Rights: This work is made available according to the conditions of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) licence. Full details of this licence are available at: http://creativecommons.org/licenses/by-nc/4.0/

Please cite the published version.
After-exercise heart rate variability is attenuated in postmenopausal women and unaffected by estrogen therapy

Paula J Harvey, BMBS, PhD, FRACP 1,2, Emma O’Donnell, PhD2,
Peter Picton, MASc, MA2, Beverley L Morris, RN2, Catherine F Notarius, PhD2,
and John S Floras, MD, DPhil, FRCPC 2,3.

Division of Cardiology at 1Women’s College Hospital, 2University Health Network and
3Mount Sinai Hospital, Department of Medicine, University of Toronto, Toronto,
Ontario, Canada.

Corresponding Author
Dr Paula J Harvey, BMBS, PhD, FRACP
Division of Cardiology, Women’s College Hospital,
Department of Medicine, University of Toronto,
76 Grenville Street
Toronto, Ontario,
M5S 1B3
Canada
Tel: 416-323-7722
Fax: 416-323-6304
Paula.harvey@wchospital.ca

Running Title: Heart Rate Variability in Menopausal Women

Financial Disclosure/Conflicts of Interest: No conflicts of interest, financial or otherwise, are declared by the author(s).

Funding: This study was supported by Grants-in-Aid T4050 and T4938 from the Heart and Stroke Foundation of Ontario. Dr. Paula Harvey was the recipient of a National Health and Medical Research Council of Australia Neil Hamilton Fairley Postdoctoral Research Fellowship and a Heart and Stroke Research Corporation of Canada Research Fellowship. Dr. Floras holds the Canada Research Chair in Investigative Cardiovascular Biology and was a Career Investigator of the Heart and Stroke Foundation of Ontario.
ABSTRACT
Objective: Delayed heart rate (HR) recovery in the immediate post-exercise period has been linked to adverse cardiovascular prognosis. The after-effects of an acute bout of exercise on HR modulation in postmenopausal women and the influence of estrogen therapy are unknown. Methods: In 13 sedentary postmenopausal women (PMW: 54±2 years; mean ± SEM), we assessed heart rate variability (HRV), an index of HR modulation, and the influence of estrogen therapy on HRV. HRV in the frequency domain was quantified during supine rest and again 60 minutes after treadmill exercise for 45 minutes at 60% VO$_2$peak. PMW were studied before and after 4 weeks of oral estradiol. To obtain reference values for the after-effects of exercise on HRV in healthy young females, 14 premenopausal women (PreM) completed the identical exercise protocol. Results: Compared with PreM, PMW demonstrated lower high frequency (HF; vagal modulation) and total HRV (P< 0.05) at rest. In PreM, all HRV values were similar before and after exercise. In contrast, in PMW after exercise, despite having identical HR to PreM, HF and total HRV were all lower (all P ≤ 0.01) compared with pre-exercise HRV values. Estrogen therapy had no effect on pre- or post-exercise values for HRV. Conclusions: When compared with PreM, PMW have identical HR but lower vagal HR modulation at rest and delayed HRV recovery after exercise. Estrogen does not restore baseline HRV or accelerate HRV recovery post-exercise, suggesting aging rather than estrogen deficiency per se may lower HRV in postmenopausal women.

Keywords: autonomic function, estrogen, exercise, heart rate variability, menopause
INTRODUCTION
Fluctuations in heart rate (HR) reflect autonomic modulation of sino-atrial discharge \(^1,2\). In cardiovascular disease diminished heart rate variability (HRV) usually reflects increased sympathetic and decreased vagal tonic HR modulation. These autonomic perturbations have been associated with increased risk for adverse cardiovascular events and mortality even in asymptomatic individuals \(^3,4\).

Exercise has profound and complex effects on autonomic HR modulation \(^5\). Importantly, these effects depend on the temporal relationship to exercise plus the cumulative effects of exercise training on autonomic tone. For example, increased cardiac sympathetic tone and coincident parasympathetic withdrawal occur during acute exercise \(^5,6\). An increased risk of death during and immediately following exercise has been attributed in part to both the magnitude and subsequent rate of restoration of normal autonomic balance \(^7\). In direct contrast to these acute effects of exercise, regular aerobic exercise training is cardioprotective, and associated independently with a reduction in cardiovascular events and total mortality \(^8\). These benefits include an increased predominance of parasympathetic heart rate modulation in the exercise trained vs. the untrained state \(^9,10\).

Potentially adverse changes in neural modulation of HR have been shown to occur following both natural \(^11,12\) and surgical \(^13\) menopause, thus suggesting that endogenous estrogen deficiency may be a factor contributing to a decrease in HRV following menopausal transition. Regular exercise is recommended as a non-pharmacological intervention to reduce cardiovascular risk and improve cardiovascular risk factor profile in postmenopausal women \(^14,15\). One mechanism contributing to the cardioprotective benefit of exercise in this population may be an enhancement of parasympathetic HR modulation in the physically trained state \(^16,17\).

Several of the cardiovascular benefits associated with exercise training may be induced rapidly, possibly after a single bout of exercise \(^18\). In this regard, we have demonstrated previously a reduction in blood pressure and an improvement in endothelial-dependent flow-mediated dilation in postmenopausal women when measured one hour following treadmill exercise for 45 minutes at 60% of peak oxygen consumption (VO\(_2\)peak) \(^19,20\). To our knowledge, the pattern and rate of HRV recovery in healthy sedentary PMW woman after a single bout of sub-maximal aerobic exercise has not been reported, but may be of clinical relevance, given the contrasting immediate versus delayed effects of exercise on autonomic modulation. Furthermore, whether HRV recovery after exercise in this population is influenced by treatment with estrogen is unknown. Thus, this study in sedentary postmenopausal women was designed to determine, using frequency domain HRV analysis: 1) the pattern and degree of recovery of tonic autonomic HR modulation measured 60 minutes after a single bout of sub-maximal dynamic exercise of a type and intensity commonly prescribed to enhance cardiovascular health; 2) whether autonomic modulation following exercise is influenced by concurrent administration of oral estrogen. To characterize the after-effects of exercise on autonomic modulation in a comparator group of healthy younger estrogen-replete females, normotensive premenopausal women were submitted to the identical protocol.
METHODS

Participants: We have previously reported the relationship between estrogen therapy, blood pressure and vascular function both before and after an acute bout of dynamic exercise in these pre- and postmenopausal women. However, thus far we have not evaluated the effects of an acute bout of exercise on their HRV. Postmenopausal women (n=13) were deemed healthy as determined by medical history, physical examination, and screening hematologic and biochemical testing performed before study entry. All were sedentary (no more than 2hrs of physical activity per week for at least the previous 6 months), normotensive (seated clinic blood pressure [BP] of ≤140/90 mm Hg), non-diabetic, non-smokers, and on no medications. To be eligible, participants reported at least 12 months of amenorrhea with the uterus intact or a previous hysterectomy. Biochemical evidence (serum follicle-stimulating hormone concentration [FSH] of ≥20 IU/L) confirmed menopausal status. No subject received hormone replacement therapy for at least 2 months before study entry.

To obtain reference HRV values to compare with postmenopausal women, 14 healthy premenopausal women were also investigated under identical experimental conditions. All premenopausal women described regular menstrual cycles, averaging 25 to 35 days. None were receiving any oral contraceptive formulations. Premenopausal women were studied during the follicular phase (estrogen relatively unopposed by progesterone) between days 5 to 13 of the menstrual cycle. Pregnancy was excluded by a negative β-human chorionic gonadotropin test.

The protocol was approved by our institutional Human Ethics Review Committee, and all participants provided signed written consent.

Protocol: All experiments were conducted in the Clinical Cardiovascular Physiology Laboratory of the Toronto General Hospital in the morning at a stable temperature between 22 and 24°C. All participants were fasted overnight and avoided exercise, alcohol, and caffeine over the 24 hours before the study. Participants lay in the supine position. An antecubital vein was cannulated for blood sampling. Heart rate (HR) was determined from lead II of an electrocardiogram recorded continuously throughout the study. Arterial BP was measured noninvasively at 1-minute intervals from the left arm by an automatic cuff recorder (Dinamap Pro 100, Critikon LLC, Tampa, Fla). A respiratory belt encircled the upper abdomen.

After 10 minutes of quiet supine rest in a semi-dark room, baseline BP and HR were acquired during 7 minutes of spontaneous breathing. All participants were then exercised on a treadmill for a total of 45 minutes. To provide similar exercise loads, the speed and grade of treadmill exercise were adjusted to maintain a target HR recorded during exercise at 60% of each individual's peak oxygen consumption (VO2peak), as measured during a graded exercise test performed on a separate day. After exercise, participants resumed the resting supine position. Post-exercise measurements commenced at 60 minutes after exercise. In postmenopausal women, this protocol was replicated 4 weeks after treatment with open-labelled oral estradiol, 2 mg/day. Participants were instructed to take this estrogen formulation at approximately the same time each morning, with the exception of the study day. After completion of the study protocol, postmenopausal women with a uterus in situ were prescribed medroxyprogesterone
acetate 10-mg tablets once daily for a period of 12 days to convert the endometrium from
the follicular to the secretory state.

Heart Rate Variability (HRV): Our approach to frequency domain analysis of HRV has
been previously described 21. Briefly, during spontaneous breathing, the ECG signal was
sampled at 1000Hz and was stored using LabView (National Instruments, Austin, TX)
for subsequent analysis. R-R intervals were analyzed using fast Fourier transformation
(FFT) to produce a spectral density curve showing a plot of the frequency of the cyclic
components of variation in the R-R interval duration against the square root of their
amplitude. A 7-minute data set comprising 2,048 data points was collected and
subsequently divided into seven segments, each containing 512 points, with one-half
overlapping of each segment. The linear trend in the data was subtracted from the data set
in each segment, and a Blackman-Harris window was applied to minimize spectral
leakage. Power spectra were obtained over a frequency range of 0.0098-0.5 Hz,
permitting the report of power spectra across very low frequency (VLF) 0.0098-0.05 Hz,
low frequency (LF: a composite of both sympathetic and parasympathetic modulation),
0.05-0.15 Hz, and high frequency (HF: an index of parasympathetic modulation), 0.15-
0.5 Hz. Frequency domains were determined in absolute units (ms²) and with log₁⁰
transformation. For all data sets, only stationary time series with ≤5% arrhythmia or
artefact were used for analyses.

Peak Aerobic Consumption: On a separate day, peak oxygen consumption (VO₂ peak)
was measured directly by open-circuit spirometry during a standard graded
cardiopulmonary exercise stress test.

Blood Sampling: Blood was collected from participants at baseline before exercise in
premenopausal women and in postmenopausal women on both study days. Serum
concentrations of FSH and 17β-estradiol were analyzed using commercially available
radioimmunoassay kits (Boehringer, Mannheim, Germany).

Statistical Analysis: All variables are expressed as mean ± standard error of the mean
(SEM). All baseline HRV absolute data variables demonstrated a positively skewed
distribution. Consequently, VLF, LF and HF were log-transformed (log₁₀) to minimize
the variance and normalize the distribution. For postmenopausal women, the average
values at each phase of the study were compared by 2-factor repeated-measures analysis
of variance (SPSS version 22.0; SPSS Inc., Chicago, IL) with estrogen and exercise as
within-subject factors. The Student-Newman-Keuls method was used for pairwise, post
hoc, multiple comparisons. In premenopausal women, paired t-tests were used to
compare differences before and after exercise. The Student t-test was used for unpaired
observations (premenopausal vs. postmenopausal women). All statistical tests were 2-
tailed with P<0.05 considered the threshold for significance.

RESULTS
Participants: Baseline physical characteristics of postmenopausal women were: mean age
54 ± 2 years, body mass index (BMI) 28.6 ± 1.5 kg/m² and mean VO₂ peak 1.33 ± 0.01
L/min. For premenopausal women, mean age was 28 ± 1 years, and mean BMI was 22 ± 1 kg/m². Mean VO2peak for this group was 1.89 ± 0.02 L/min. These VO2peak values were 73% and 85% of predicted, respectively. Each of these characteristics were significantly different (P<0.05) between the groups.

**Blood Sampling:** As expected, baseline pre-estrogen serum measures of 17 beta-estradiol in postmenopausal women were lower (P<0.001) compared with post-estrogen (22 ± 3.3 vs. 998 ± 220 pmol/L, respectively). FSH (IU/L) was significantly reduced (P<0.001) by estrogen therapy (78 ± 3 vs. 37 ± 6, pre- versus post-estrogen, respectively). In the premenopausal group mean serum estradiol measured in the follicular phase was 187 ± 28 pmol/L.

**Resting Heart Rate and Arterial Pressure:** The BP and HR values of postmenopausal women appear in Table 1. With estrogen resting systolic BP was unchanged, but diastolic blood pressure (DBP) and mean arterial pressure (MAP) were lower (P< 0.01). Despite these changes there were no significant differences between pre- and post-estrogen baseline resting values for HR. Resting HR and BP of premenopausal and postmenopausal women were similar (P>0.05).

**Resting HRV:** Baseline frequency domain measures of HRV in postmenopausal women before and after estrogen are shown in Table 1. At rest, postmenopausal women demonstrated similar LF compared with premenopausal women both pre- and post-estrogen. In contrast, resting HF were lower (P<0.05) in postmenopausal women both before and after estrogen when compared with premenopausal women.

**Exercise:** All participants completed the full 45-minute exercise protocol. In postmenopausal women, heart rates achieved during exercise were 116 ± 4 and 114 ± 3 beat/min pre- and post-estrogen, respectively. These values corresponded to 101% ± 1% and 100% ± 1% of the target exercise HR. Premenopausal women achieved mean heart rate of 128±3 beats/min which corresponded to 100±2% of the target exercise heart rate. Exercise increased systolic blood pressure (SBP) by 17 ± 3 mmHg before estrogen as compared with 9 ± 4 mmHg post-estrogen (P=0.12). Exercise increased average SBP by 10±4 mmHg in the premenopausal group (P=0.15 premenopausal vs. postmenopausal pre-estrogen).

**After-Exercise Heart Rate and Arterial Pressure:** One hour after exercise, in postmenopausal women, SBP and DBP were lower (P<0.05) both before and after estrogen therapy (Table 1). One hour after exercise, in premenopausal women, SBP and DBP were unchanged (P>0.05). HR post exercise was elevated (P>0.05) and identical in the 2 groups.

**After-Exercise Heart Rate Variability:** In postmenopausal women, two-way analysis of variance identified that exercise significantly lowered all indices of HRV, except LF/HF, which remained unaltered (P>0.05; Table 1). In contrast, no significant main effect for estrogen therapy was detected. After-exercise, postmenopausal women pre-estrogen therapy demonstrated lower (P<0.05) LF, HF and Total HRV compared with
premenopausal women (Table 1). Estrogen therapy did not alter \((P>0.05)\) resting or post-exercise frequency domain measures of HRV. In premenopausal women, one hour after exercise, despite a similar heart rate, all HRV measures were unchanged from pre-exercise values \((P>0.05)\).

**DISCUSSION**

This study had two aims. The first was to compare the after-effects of a single bout of dynamic exercise on cardiac autonomic HR modulation assessed by frequency domain analysis of HRV in healthy sedentary premenopausal and postmenopausal women. The second was to investigate the influence of exogenous estrogen on the post-exercise HRV responses in postmenopausal women. Consistent with previous literature \(^{11,17,23,24}\) HF spectral power, an index of parasympathetic modulation of heart rate, was lower at rest in postmenopausal compared with premenopausal women. Our key new findings were: 1) in healthy sedentary premenopausal women, frequency-domain indexes of heart rate modulation recorded one hour post submaximal dynamic exercise were not significantly reduced from pre-exercise values. In contrast to these findings in premenopausal women, in postmenopausal women; 2) HF and LF remained suppressed below pre-exercise values at one hour post acute exercise; and 3) pre-treatment with chronic oral estrogen did not augment vagal modulation at rest, or enhance HRV recovery in the post-exercise period, suggesting delayed recovery of autonomic modulation. In view of recent concerns that these indices of HRV are simply a function of HR \(^{25}\), it is important to emphasize that these differences between premenopausal and postmenopausal women occurred despite identical heart rates after exercise.

The present finding of attenuated HF power, an index of parasympathetic modulation of HR, in postmenopausal women at baseline rest when compared with a comparator group of premenopausal women is concordant with that of other investigators who have shown reductions in HRV in women following both natural \(^{11,16,23,24}\) and surgical \(^{13}\) menopause. However, both aging and postmenopausal hormonal deficiency may contribute to changes in autonomic heart rate modulation in the postmenopausal period. We did not show any significant influence on resting heart rate or augmentation of resting HRV in our postmenopausal women following administration of oral estrogen, suggesting that the difference in HRV observed between pre- and postmenopausal women may be more consistent with aging than estrogen deficiency.

Previous studies of the effects of exogenous estrogen on resting cardiac autonomic heart rate modulation in postmenopausal women have yielded inconsistent results. In some studies, exogenous estrogen has been shown to attenuate, although not necessarily fully reverse, menopause-associated decreases in HRV through enhancement of cardiac vagal and attenuation of cardiac sympathetic tone \(^{11,13,23,24}\) whereas other studies have been unable to replicate this finding \(^{26,27}\). These inconsistencies may reflect differences in subject baseline characteristics, in the type, dose, mode of administration and timing of exogenous estrogen and in the experimental condition. For example, Neves et al \(^{24}\) found that estrogen partially alleviated the decline in HRV in their postmenopausal women but only when acquired in the seated but not in the supine position.

Importantly, these previous investigators determined HRV in postmenopausal women pre and post-estrogen only under resting conditions. Little is known of the
influence of exogenous estrogen on HRV following different stimuli known to influence autonomic heart rate regulation. For the purpose of this analysis we were particularly interested in the after-effects of a single bout of dynamic exercise. Exercise has complex effects on sympathovagal heart rate modulation. Regular physical activity is associated with increased HRV and in particular a shift towards enhanced parasympathetic modulation. These changes are believed to contribute to improved cardiac electrical stability, and thus to the well documented cardioprotective benefits of exercise training \(^9, 10\). However, in contrast to these well recognized cardioprotective effects of regular physical activity, risk of sudden cardiac death is increased during and immediately after exercise \(^7, 28\). It is generally agreed that during exercise, there is parasympathetic withdrawal and sympathetic excitation \(^5, 6\). Delayed heart rate recovery in the immediate post exercise period is postulated to reflect delayed parasympathetic recovery and has been shown to be a predictor of sudden cardiac death. However, data pertaining to the kinetics of recovery of autonomic function after cessation of exercise beyond the very immediate post-exercise period are much less well explored and the timing and pattern of the recovery of autonomic regulation back to baseline is debated \(^6, 18, 29\).

Of the relatively small number of studies examining the delayed effects of exercise on autonomic modulation as measured by HRV, the majority have been undertaken in young men. It is unclear whether parasympathetic withdrawal or alternatively sympathetic withdrawal predominates in the delayed post-exercise period in these studies. Intensity and type of exercise (e.g. interval vs. constant vs. resistance), timing and position of subject during acquisition of recordings post exercise vary between these studies and likely contribute to the heterogeneous findings in otherwise similar young male cohorts \(^6, 18, 30-35\).

There is no present published literature concerning HRV responses one hour after exercise in either healthy untrained premenopausal or postmenopausal women. Figueroa et al compared HRV at 20 minutes post walk exercise at 65\% VO\(_2\)peak in lean (n=8) and obese (n=8) middle-aged women (40-60 years) with type 2 diabetes, and 12 obese women without type 2 diabetes \(^36\). These investigators reported suppressed HF, more marked in the obese and diabetic than lean and diabetic participants post-exercise. More delayed responses post-exercise were not studied, nor were women defined by menopausal status. We found no delayed post-exercise effect on HRV in our premenopausal women, but our postmenopausal women had persistently depressed HF and Total HRV values at one hour after acute submaximal walking exercise. Although we excluded participants with glucose intolerance, hyperlipidemia and hypertension, it is possible that the higher BMI and lower cardiorespiratory fitness of our postmenopausal women compared to premenopausal women contributed to the observed attenuated return of post-exercise HF to pre-exercise values. In support of this concept, previous studies report that elevated BMI is inversely and cardiorespiratory fitness positively associated with HRV \(^37, 38\).

**Limitations:** We did not record HR during controlled breathing, but it has been demonstrated previously in middle-aged volunteers studied supine that paced and spontaneous breathing provide similar information if recording periods are short and if spontaneous breaths fall within the high-frequency band \(^39\) as it was in our participants both before and after exercise.
Conclusions: In summary, we have shown that in sedentary premenopausal women HRV power spectra density recovers to pre-exercise values when measured an hour after a single bout of treadmill exercise performed at a submaximal intensity that is comparable to prescriptions recommended for maintenance of cardiovascular health. In contrast, postmenopausal women exhibit significant reductions in HF, LF and total HRV spectral power after exercise. This sustained attenuation, particularly of tonic vagal heart rate modulation, is not an artefact of HR, since heart rates after exercise were similar in the pre- and postmenopausal women. Four weeks of estrogen replacement did not increase resting HRV and did not accelerate post-exercise HRV recovery in postmenopausal women. These observations suggest aging, and mechanisms consequent to the accretion of other age-related changes, such as a high BMI and low cardiorespiratory fitness, contribute to the lower resting HRV and delayed HRV recovery one hour post exercise in our postmenopausal women.

Low resting HRV is a recognized marker of adverse prognosis in cardiac patients and healthy populations (Tsuji, 1996; Dekker, 2000). During, and recovery from, exercise is suggested to be a vulnerable window for dysrhythmias and fatal events (Lahiri 2008). Autonomic evaluation of postmenopausal women during recovery from exercise may therefore also be of prognostic importance, particularly in light of current directives to actively encourage this population to engage in physical activity as part of a healthy lifestyle (Manson 2002; Manson 1999). Thus, delineation of the additional information that could be yielded from post-exercise recovery of HRV in response to both acute and chronic exercise training, and how estrogen influences this process, is of significance to postmenopausal women. Understanding the short and long-term effects of exercise on the cardiac autonomic nervous system will provide insight into whether regular physical activity and improved fitness can over time positively influence the post-exercise recovery of vagal heart rate modulation of postmenopausal women.

ACKNOWLEDGMENTS
We appreciate the time and effort expended by the volunteer participants. We also thank the staff of the Clinical Cardiovascular Physiology Laboratory at the Toronto General Hospital, Toronto.
REFERENCES

Table 1. Pre- and post-exercise HR, BP and HRV in premenopausal women and healthy postmenopausal women pre- and post-estrogen therapy.

<table>
<thead>
<tr>
<th></th>
<th>PreM (n=14)</th>
<th>PMW (n=13)</th>
<th>PMW (n=13)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre Ex</td>
<td>Post Ex</td>
<td>Pre Ex</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>101±2</td>
<td>98±2</td>
<td>108±3</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>61±2</td>
<td>61±2</td>
<td>64±2</td>
</tr>
<tr>
<td>MAP (mmHg)</td>
<td>74±2</td>
<td>73±2</td>
<td>79±2</td>
</tr>
<tr>
<td>HR (beats/min)</td>
<td>59±2</td>
<td>74±3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>61±3</td>
</tr>
<tr>
<td>LF (log10)</td>
<td>2.88±0.16</td>
<td>2.76±0.15</td>
<td>2.72±0.10</td>
</tr>
<tr>
<td>HF (log10)</td>
<td>3.08±0.16</td>
<td>2.82±0.19</td>
<td>2.64±0.12&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>VLF (log10)</td>
<td>2.90±0.11</td>
<td>2.86±0.13</td>
<td>2.85±0.12</td>
</tr>
</tbody>
</table>

All values are mean ± SEM.

DBP, diastolic blood pressure; HF, high frequency power spectra; HR, heart rate; LF, low frequency power spectra; log10, log 10 transformed data; MAP, mean arterial pressure; mmHg, millimetres of mercury; PMW, postmenopausal women; Pre Ex, pre-exercise; PreM, premenopausal women; Post Ex, post-exercise; SBP, systolic blood pressure; VLF, very low frequency power spectra.

<sup>a</sup> P<0.05 vs pre-exercise, within groups

<sup>b</sup> P<0.05 vs PMW pre-exercise, pre-estrogen

<sup>c</sup> P <0.05 vs PreM post-exercise

<sup>d</sup> P <0.05 vs PreM pre-exercise